Washington University School of Medicine psychedelic research trials
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
Washington University School of Medicine is listed with 9 registered studies counted here, in St Louis, United States. By compound: 4 psilocybin and 5 ketamine. By registry status: 1 not yet recruiting, 5 completed and 3 withdrawn. By phase: 1 early phase 1, 1 phase 1, 4 phase 2, 1 phase 3 and 2 not applicable. Reported start years run from 2012 (earliest) to 2026 (latest).
Institution name, city and country are copied from the research site linked to each registry record. A study counts once per institution, and a study tagged with more than one compound is counted under each compound.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 9 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 4 |
| Ketamine | 5 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Not yet recruiting | 1 | 11% |
| Completed | 5 | 56% |
| Withdrawn | 3 | 33% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 1 | 11% |
| Phase 1 | 1 | 11% |
| Phase 2 | 4 | 44% |
| Phase 3 | 1 | 11% |
| Not applicable | 2 | 22% |
Registered studies
All counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Compound |
|---|---|---|---|---|---|
| Psilocybin-Assisted Therapy as a Treatment for Depression | NCT07582120 | Not yet recruiting | Phase 2 | 2026-06-01 | Psilocybin |
| The Perinatal Synergistic Multi-component Intervention to alLeviate dEpressive Symptoms. A Case Series | NCT06048263 | Withdrawn | Phase 2 | 2025-10-15 | Ketamine |
| Psilocybin for Major Depressive Disorder | NCT05675800 | Withdrawn | Phase 2 | 2024-01-01 | Psilocybin |
| KET-RO Plus RO DBT for Treatment Resistant Depression | NCT06138691 | Completed | Phase 1 | 2023-10-04 | Ketamine |
| PET Synaptogenesis After Psilocybin In DEpression Recovery | NCT05601648 | Withdrawn | Phase 2 | 2023-07-01 | Psilocybin |
| Ketamine for Postoperative Avoidance of Depressive Symptoms: The K-PASS Feasibility Trial | NCT05233566 | Completed | Phase 3 | 2022-04-25 | Ketamine |
| Precision Functional Brain Mapping in Psilocybin | NCT04501653 | Completed | Early Phase 1 | 2021-06-01 | Psilocybin |
| Cognitive Recovery After Electroconvulsive Therapy and General Anesthesia | NCT02761330 | Completed | Not applicable | 2016-04-01 | Ketamine |
| Treatment Resistant Depression (Pilot) | NCT01179009 | Completed | Not applicable | 2012-04-01 | Ketamine |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.